Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Work In Process: 2019-2025

Historic Work In Process for Ptc Therapeutics (PTCT) over the last 5 years, with Sep 2025 value amounting to $41.8 million.

  • Ptc Therapeutics' Work In Process rose 71.14% to $41.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.8 million, marking a year-over-year increase of 71.14%. This contributed to the annual value of $12.2 million for FY2024, which is 32.10% down from last year.
  • Per Ptc Therapeutics' latest filing, its Work In Process stood at $41.8 million for Q3 2025, which was up 71.67% from $24.4 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Work In Process registered a high of $41.8 million during Q3 2025, and its lowest value of $7.0 million during Q2 2022.
  • For the 3-year period, Ptc Therapeutics' Work In Process averaged around $22.2 million, with its median value being $22.2 million (2024).
  • Its Work In Process has fluctuated over the past 5 years, first skyrocketed by 247.88% in 2023, then plummeted by 41.09% in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Work In Process stood at $7.7 million in 2021, then soared by 82.28% to $14.1 million in 2022, then rose by 27.83% to $18.0 million in 2023, then crashed by 32.10% to $12.2 million in 2024, then spiked by 71.14% to $41.8 million in 2025.
  • Its last three reported values are $41.8 million in Q3 2025, $24.4 million for Q2 2025, and $13.1 million during Q1 2025.